Two-thirds of health care providers agree or strongly agree with expanding recommendations for the new 20-valent pneumococcal conjugate vaccine (PCV20), according to research published in the Sept. 8 ...

There is certainly some room for debate on this question, which highlights some of the limitations of both the evidence for efficacy of newer vaccine products as well as what clinicians and patients ...

STRIDE-3 (NCT05425732) is a Phase 3, randomized, double-blind, active comparator-controlled study evaluating the safety, tolerability, and immunogenicity of V116 compared to PCV20 in adults 18 years ...

Please provide your email address to receive an email when new articles are posted on . The Advisory Committee on Immunization Practices unanimously agreed to recommend PCV20 for children. Advisors ...

Questions are answered by experts at the Oregon Health Authority, other state agencies or community partners. Questions and answers are republished by permission. Q: I am in my 70s and have previously ...

V116 elicited noninferior immune responses compared with PCV20 for all 10 serotypes common to both vaccines. Merck’s investigational 21-valent pneumococcal conjugate vaccine, V116, elicited ...

After the fourth dose, the titers were approximately 15-fold higher with 25vPnC than PREVNAR 20.

Credit: Getty Images. Findings from this survey were presented at the October 2022 ACIP meeting. While health care providers understand the value of pneumococcal vaccination, there appear to be ...

Vaxcyte Inc. (NASDAQ:PCVX) is one of the best mid cap stocks to buy with highest upside potential. On May 6, Vaxcyte achieved ...

Vaxcyte Inc. (NASDAQ:PCVX) on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate ...